- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance - Results from more than 1,000 high-risk patients were consistent with previous data - Findings from BLAZE-4 trial provide data on lower doses of bamlanivimab and etesevimab together - Media and

INDIANAPOLIS , Jan. 22, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly , extending Lilly 's

INDIANAPOLIS , Jan. 21, 2021 /PRNewswire/ -- Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The Phase 3 BLAZE-2 COVID-19 prevention trial – conducted in

INDIANAPOLIS and UTRECHT, The Netherlands , Jan. 19, 2021 /PRNewswire/ -- Loxo Oncology at Lilly , a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies, today announced a research

INDIANAPOLIS , Jan. 15, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021 . Lilly will also conduct a conference call on that day with the investment community and media to further detail the

Fund will provide support for minority-owned early-stage healthcare companies and is a component of Lilly's racial justice efforts INDIANAPOLIS , Jan. 15, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced a $30 million limited partner investment in Unseen Capital Health Fund LP

INDIANAPOLIS , Jan. 14, 2021 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Gabrielle Sulzberger as a new member, effective January 25, 2021 . As a member of Lilly 's board, she will serve on both the Audit Committee and the Ethics and Compliance Committee .

RIDGEFIELD, Conn. and INDIANAPOLIS, Jan. 11, 2021 /PRNewswire/ -- The U.S.   Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance ® (empagliflozin) which is being investigated as a potential new treatment to reduce the risk of cardiovascular death

INDIANAPOLIS , Jan. 11, 2021 /PRNewswire/ -- Donanemab, an investigational antibody that targets a modified form of beta amyloid called N3pG, showed significant slowing of decline in a composite measure of cognition and daily function in patients with early symptomatic Alzheimer's disease compared

INDIANAPOLIS , Jan. 4, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will participate in the 39 th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 . David A. Ricks , Lilly 's chairman and chief executive officer, will participate in a virtual fireside chat at 8:20 a.m.